Direct AMPK activation extends lifespan by over 25% in three species

Lifespan extended by more than 25 percent in three distinct organisms after researchers administered a drug that directly activates a specific cellular energy sensor. The findings, published in Aging Cell, demonstrate that targeting the enzyme AMPK with the compound 991 yields significant longevity benefits in fission yeast, nematode worms, and fruit flies.

The mechanism of emergency budgeting

Cells respond to low energy availability by reducing costly activities such as protein synthesis and fat storage while mobilizing existing fuel reserves. This process mirrors household budget cuts during financial shortages. Central to this regulatory system is AMP-activated protein kinase (AMPK), a molecular sensor that triggers when cellular energy levels drop.

Previous research has linked AMPK activity to longevity through genetic modifications and dietary interventions in worms and flies. Metformin, a common diabetes medication, indirectly activates AMPK and has been studied for potential geroprotective effects. A 2013 Nature Communications study noted that low-dose metformin increased mean lifespan by approximately 6 percent in one strain of male mice, though higher doses proved toxic.

Testing direct pathway activation

Unlike metformin, which affects multiple cellular systems and whose effects in worms may depend on gut bacteria, compound 991 binds directly to AMPK. The research team confirmed that 991 activated the enzyme in all three test organisms before assessing longevity outcomes. In fruit flies, the treatment also reduced body fat without altering food intake.

Helena Cochemé of the MRC Laboratory of Medical Sciences stated in an institute press release that this study represents the first demonstration that directly targeting AMPK with a drug can provide longevity benefits in living organisms. Crucially, the lifespan extension disappeared in worms and yeast engineered to lack functional AMPK, indicating the drug worked through the intended pathway rather than via side effects.

Dosage limits and mammalian trials

Charalampos Rallis of Queen Mary University of London emphasized that increased activation does not always correlate with better outcomes. Higher doses of 991 shortened lifespan in some fly and yeast experiments. Rallis warned against interpreting these results as a recommendation for supplements, noting that the switch must be set correctly rather than jammed on.

The researchers also tested 991 in mice using nanoparticle packaging for three weeks. This phase did not assess lifespan but examined liver changes. In a small group of normal mice—three treated and three controls—the drug appeared to shift cells toward an energy-efficient, maintenance-focused state. Indicators included improved energy production, increased mitochondria, and suppression of mTOR, a growth-promoting pathway.

The inhibition of mTOR is notable given its historical link to aging. A landmark 2009 Nature study showed that rapamycin extended mouse lives by dampening this same pathway. However, the current research only confirms that 991 triggered similar biological changes in mice, not that it extends their lifespan.

Human relevance and safety concerns

Direct AMPK activators have seen limited human testing. PXL770 reached a Phase 2a trial involving 120 people for fatty liver disease; it was generally well tolerated but failed to meet primary endpoints. Another direct activator, MK-8722, improved glucose control in mice and monkeys but caused cardiac enlargement, highlighting the risks of manipulating fundamental metabolic switches.

The study establishes that 991 can push cells into an energy-conserving state and lengthen life across three branches of the evolutionary tree. Determining whether this effect translates to mammals remains the next critical experimental step.